{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:18:25Z","timestamp":1789057105011,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.vaccine.2022.02.067","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T15:24:48Z","timestamp":1645889088000},"page":"2173-2183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom"],"prefix":"10.1016","volume":"40","author":[{"given":"Vincent","family":"Daniels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Patterson-Lomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Gomez-Lievano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Saah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Luxembourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Velicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elamin","family":"Elbasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vaccine.2022.02.067_b0005","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/jnci\/85.12.958","article-title":"Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia","volume":"85","author":"Schiffman","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2022.02.067_b0010","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ypmed.2011.08.017","article-title":"Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies","volume":"53","author":"Tota","year":"2011","journal-title":"Prev Med"},{"issue":"11","key":"10.1016\/j.vaccine.2022.02.067_b0015","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1086\/516784","article-title":"A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion","volume":"195","author":"Plummer","year":"2007","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2022.02.067_b0020","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jnci\/djn044","article-title":"Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections","volume":"100","author":"Rodriguez","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.vaccine.2022.02.067_b0025","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pky045","article-title":"Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6\/11\/16\/18\/31\/33\/45\/52 and 58","volume":"2","author":"de Sanjose","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"6","key":"10.1016\/j.vaccine.2022.02.067_b0030","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.067_b0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijporl.2009.09.004","article-title":"The role of HPV type in recurrent respiratory papillomatosis","volume":"74","author":"Donne","year":"2010","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.067_b0040","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/cncy.21738","article-title":"HPV vaccination in Southern Africa: A jab of hope in the fight against cervical cancer","volume":"124","author":"Michelow","year":"2016","journal-title":"Cancer Cytopathol"},{"issue":"17","key":"10.1016\/j.vaccine.2022.02.067_b0045","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2022.02.067_b0050","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ygyno.2009.04.035","article-title":"Age-appropriate use of human papillomavirus vaccines in the U.S","volume":"114","author":"Castle","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"22","key":"10.1016\/j.vaccine.2022.02.067_b0055","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.067_b0060","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-4035","article-title":"Three-year follow-up of 2-dose versus 3-dose HPV vaccine","volume":"147","author":"Bornstein","year":"2021","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.vaccine.2022.02.067_b0065","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/14760584.2017.1383158","article-title":"9-valent human papillomavirus vaccine: A review of the clinical development program","volume":"16","author":"Luxembourg","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2022.02.067_b0070","unstructured":"Oxford Vaccine Group. Vaccine Knowledge Project. HPV (human papillomavirus). Accessed on: April 19, 2021. Available from: https:\/\/vk.ovg.ox.ac.uk\/vk\/hpv."},{"key":"10.1016\/j.vaccine.2022.02.067_b0075","unstructured":"National Heath System. HPV vaccine overview. Accessed on: April 21, 2021. Available from: https:\/\/www.nhs.uk\/conditions\/vaccinations\/hpv-human-papillomavirus-vaccine\/."},{"issue":"32","key":"10.1016\/j.vaccine.2022.02.067_b0080","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1016\/j.vaccine.2018.02.087","article-title":"Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study","volume":"36","author":"Sankaranarayanan","year":"2018","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2022.02.067_b0085","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1016\/j.vaccine.2017.12.078","article-title":"Evidence for single-dose protection by the bivalent HPV vaccine\u2014Review of the Costa Rica HPV vaccine trial and future research studies","volume":"36","author":"Kreimer","year":"2018","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.067_b0090","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jnci\/djaa011","article-title":"Evaluation of durability of a single dose of the bivalent HPV vaccine: The CVT trial","volume":"112","author":"Kreimer","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"32 Pt A","key":"10.1016\/j.vaccine.2022.02.067_b0095","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1016\/j.vaccine.2018.01.057","article-title":"Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs","volume":"36","author":"Markowitz","year":"2018","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.02.067_b0100","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.vaccine.2019.12.017","article-title":"Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials","volume":"38","author":"Whitworth","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.02.067_b0105","unstructured":"Henschke N, Bergman H, Buckley B, Cogo E, Probyn K, Sguassero Y, et al. Effectiveness and immunogenicity of one dose of HPV vaccine compared with no vaccination, two doses, or three doses (Cochrane Response). Accessed on: April 6, 2021. Available from: https:\/\/www.who.int\/immunization\/sage\/meetings\/2019\/october\/4_._FINAL_One_dose_HPV_vaccine_report_v4.0_20190820.pdf."},{"issue":"2","key":"10.1016\/j.vaccine.2022.02.067_b0110","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/aje\/kwx253","article-title":"Human papillomavirus vaccine effectiveness against incident genital warts among female health-plan enrollees","volume":"187","author":"Hariri","year":"2018","journal-title":"United States Am J Epidemiol"},{"issue":"27","key":"10.1016\/j.vaccine.2022.02.067_b0115","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1016\/j.vaccine.2020.04.041","article-title":"A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination","volume":"38","author":"Batmunkh","year":"2020","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.02.067_b0120","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/aje\/kwz253","article-title":"Effectiveness of 1, 2, and 3 doses of human papillomavirus vaccine against high-grade cervical lesions positive for human papillomavirus 16 or 18","volume":"189","author":"Johnson Jones","year":"2020","journal-title":"Am J Epidemiol"},{"issue":"12","key":"10.1016\/j.vaccine.2022.02.067_b0125","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18571","article-title":"Prevalence of human papillomavirus infection by number of vaccine doses among US women","volume":"2","author":"Sonawane","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.vaccine.2022.02.067_b0130","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/infdis\/jiz555","article-title":"Human papillomavirus vaccine effectiveness against HPV infection: Evaluation of one, two, and three doses","volume":"221","author":"Markowitz","year":"2020","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2022.02.067_b0135","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/cncr.32700","article-title":"Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study","volume":"126","author":"Rodriguez","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.067_b0140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/infdis\/jiz422","article-title":"Cervical intraepithelial neoplasia rates in British Columbia women: A population-level data linkage evaluation of the school-based HPV immunization program","volume":"221","author":"Racey","year":"2020","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2022.02.067_b0145","first-page":"A349","article-title":"P832 Effectiveness of the quadrivalent HPV vaccine against HSIL and CIN: a data-linkage study","volume":"95","author":"Donken","year":"2019","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2022.02.067_b0150","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7584","article-title":"Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model","volume":"350","author":"Jit","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2022.02.067_b0155","unstructured":"World Health Organization. Evidence based recommendations on human papilloma virus (HPV) vaccines schedules. Accessed on: May 5, 2021. Available from: https:\/\/www.who.int\/immunization\/sage\/meetings\/2014\/april\/1_HPV_Evidence_based_recommendationsWHO_with_Appendices2_3.pdf?ua=1."},{"issue":"32","key":"10.1016\/j.vaccine.2022.02.067_b0160","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1016\/j.vaccine.2018.04.061","article-title":"Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country","volume":"36","author":"Burger","year":"2018","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2022.02.067_b0165","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/S1473-3099(20)30860-4","article-title":"Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis","volume":"21","author":"Drolet","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.02.067_b0170","doi-asserted-by":"crossref","unstructured":"Prem K, Choi YH, B\u00e9nard \u00c9, Burger EA, Mmath LH, Laprise J-F, et al. Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis. medRxiv. 2021:2021.02.08.21251186.","DOI":"10.1101\/2021.02.08.21251186"},{"key":"10.1016\/j.vaccine.2022.02.067_b0175","unstructured":"Kim JJ. Could 1 dose be less efficacious than 2 doses but still be a great public health intervention? HPV World. Accessed on: April 8, 2021. Available from: https:\/\/www.hpvworld.com\/media\/29\/media_section\/0\/5\/1605\/kim.pdf."},{"issue":"7","key":"10.1016\/j.vaccine.2022.02.067_b0180","first-page":"775","article-title":"Efficacy of fewer than three doses of an HPV-16\/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials","volume":"16","author":"Kreimer","year":"2015","journal-title":"LancetOncol"},{"issue":"32","key":"10.1016\/j.vaccine.2022.02.067_b0185","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1016\/j.vaccine.2018.02.023","article-title":"Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa","volume":"36","author":"Tan","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.02.067_b0190","unstructured":"Joint Committee on Vaccination and Immunisation. Statement on the delivery of the HPV vaccine. Accessed on: May 5, 2021. Available from: https:\/\/www.gov.uk\/government\/publications\/delivery-of-the-hpv-vaccine-and-impact-of-school-closures-statement-from-the-jcvi\/joint-committee-on-vaccination-and-immunisation-statement-on-the-delivery-of-the-hpv-vaccine."},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.067_b0195","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"42","key":"10.1016\/j.vaccine.2022.02.067_b0200","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","article-title":"Impact of vaccinating boys and men against HPV in the United States","volume":"28","author":"Elbasha","year":"2010","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.02.067_b0205","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1080\/21645515.2020.1852870","article-title":"Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States","volume":"17","author":"Daniels","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2022.02.067_b0210","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"issue":"9576","key":"10.1016\/j.vaccine.2022.02.067_b0215","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.vaccine.2022.02.067_b0220","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.067_b0225","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"issue":"9574","key":"10.1016\/j.vaccine.2022.02.067_b0230","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.02.067_b0235","unstructured":"Office of National Statistics (United Kingdom). Dataset: estimates of the population for the UK, England and Wales, Scotland and Northern Ireland. Accessed on: June 25, 2021. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/populationestimatesforukenglandandwalesscotlandandnorthernireland."},{"key":"10.1016\/j.vaccine.2022.02.067_b0240","unstructured":"World Health Organization. MI4A: Vaccine purchase data. Accessed on: April 20, 2021. Available from: https:\/\/www.who.int\/immunization\/programmes_systems\/procurement\/mi4a\/platform\/module1\/en\/."},{"key":"10.1016\/j.vaccine.2022.02.067_b0245","unstructured":"National Institute for Health and Clinical Excellence (NICE). Updated guide to the methods of technology appraisal. Accessed on: April 20, 2021. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.067_b0250","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.vaccine.2022.02.067_b0255","first-page":"e423","article-title":"Fewer than three doses of HPV vaccine","volume":"16","author":"Jit","year":"2015","journal-title":"LancetOncol"},{"key":"10.1016\/j.vaccine.2022.02.067_b0260","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5775","article-title":"Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model","volume":"343","author":"Jit","year":"2011","journal-title":"BMJ"},{"issue":"26","key":"10.1016\/j.vaccine.2022.02.067_b0265","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1016\/j.vaccine.2014.03.098","article-title":"Two-dose strategies for human papillomavirus vaccination: how well do they need to protect?","volume":"32","author":"Jit","year":"2014","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22002201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22002201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:11:12Z","timestamp":1759403472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22002201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":53,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0264410X22002201"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.067","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA and The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}